

LETTER TO THE EDITOR

Open Access



Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine

Sophie Voruz¹ , Laurence de Leval² and Anne Cairoli^{1*}

Abstract

Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a very rare lymphoma with an aggressive clinical course and a dismal outcome. The prognosis is linked to a pronounced resistance to chemotherapy and radiotherapy. No standard treatment approach is defined due to the low frequency of the disease and lack of prospective studies. CD30 is expressed in almost half of the cases of PCGD-TCL, which offers a potential therapeutic option. We report the successful treatment of a 68-year-old man who suffered PCGD-TCL with a combination of Brentuximab Vedotin and Gemcitabine after the failure of two lines of previous chemotherapy. CD30 expression was only partial. The treatment was very well tolerated and allowed the patient to benefit from allogeneic hematopoietic stem cell transplantation.

Keywords: Primary cutaneous gamma-delta T-cell lymphoma, Targeted treatment, Cutaneous T-cell lymphoma, Refractory disease

To the Editor

Primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL) represents <1% of cutaneous T-cell lymphomas [1]. The clinical course is mostly aggressive with a median survival rate between 11 and 20% at 5 years with ranges from 15 to 31 months after diagnosis [2–4]. The prognosis is even worse for patients with predominantly subcutaneous fat involvement, as in this case, compared to those with epidermal or dermal disease only, reaching 10 months [2]. The prognosis is linked to a pronounced resistance to chemotherapy and radiotherapy. No standard treatment approach is defined due to the low frequency of the disease and lack of prospective studies. Here, we report the case of a patient with

refractory PCGD-TCL who was successfully treated with a combination of Brentuximab Vedotin and Gemcitabine.

A 68-year-old man presented with numerous panniculitis-like thickened erythematous red-brownish painless cutaneous plaques that had developed over the past 3 months. Some lesions had evolved with skin ulceration. They were first noticed on the lower extremities and subsequently involved the trunk, the upper extremities and the face (Fig. 1). The patient reported no other symptoms and particularly no pruritus. PET scan showed multiple subcutaneous metabolic lesions with maximum standard uptake values (SUV) of 12.3 mg/l, without hepatosplenic or systemic involvement.

A biopsy of a calf lesion showed a lymphoid infiltrate involving the subcutaneous fat and extending to the dermis while preserving the epidermis. The infiltrate consisted of medium to large atypical lymphocytes admixed with a large number of histiocytes, featuring fat cell rimming and producing a panniculitis-like

*Correspondence: anne.cairoli@chuv.ch

¹ Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Rue du Bugnon 46, CH – 1011 Lausanne, Switzerland
Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Fig. 1 The panniculitis-like lesions with adjacent erythematous patches and skin ulceration




Fig. 2 Histopathology of a skin biopsy. **A** Panoramic view showing an infiltrate predominantly involving the subcutaneous fat lobules. **B** Subcutaneous infiltrate with a panniculitis-like pattern, and focal dermal involvement. **C** CD3 immunostaining showing diffuse CD3 positivity and highlighting the subcutaneous and dermal distribution of the infiltrate. **D** High-power view of the subcutaneous fat showing an infiltrate of medium to large atypical lymphoid rimming the adipocytes and admixed to histiocytes. **E** Strong expression of TCR delta by the T cells. **F** Strong expression of perforin by the T cells. **G** Partial expression of CD30 by the T cells

pattern (Fig. 2). By immunohistochemistry the lymphoid cells were positive for CD2 and CD3, weakly positive for CD56, and expressed several cytotoxic markers (TIA-1 granzyme B, and perforin). They were positive for TCR delta and negative for TCR betaF1, CD4, CD8, CD5, CD7 and CD57. Moderate to strong CD30 expression was detected in a subset of the lymphoid cells (< 50%). Ki67 proliferation fraction was 80%.

PCR studies documented a monoclonal rearrangement of TRG and TRB genes.

A diagnosis of PCGD-TCL was established, and the patient was administered CHOEP chemotherapy and prophylactic intrathecal chemotherapy. After 2 cycles, PET-CT showed progressive disease, and the patient developed B symptoms. Therapy was switched to B-CHP; after two cycles, no improvement was

clinically observed and the PET-CT showed only a slight response of some of the lesions (Deauville score 5). The patient condition worsened with ECOG 3. A third-line therapy was initiated with brentuximab-vedotin (1.8 mg/kg D1) and gemcitabine (800 mg/m² D1 and D8). After two cycles, we observed a very good partial remission and the patient received four additional cycles very well tolerated, and recovered an excellent general condition. After 6 cycles, clinical response was almost complete; PET-CT scan showed very few persistent lesions with a SUVmax < 3.5 mg/l in the upper limbs and trunk that were difficult to interpret as residual tumor versus inflammatory response. Nine months after the diagnosis, an allogeneic stem cell transplantation (ASCT) with a haplo-identical donor was performed after sequential clofarabine-based conditioning regimen. The patient is still in clinical complete response 9 months after the transplant.

Anthracycline-based treatment is often used to treat PCGD-TCL despite disappointing results [5]. ASCT has shown favorable and durable outcome for some patients [5–9], however maximal lowering of the disease burden is still necessary before proceeding to transplant. As CD30 is expressed in almost half of the cases of PCGD-TCL [10], brentuximab-vedotin is a potential therapeutic option. Recently, brentuximab-vedotin has shown efficacy in four patients, even if the expression of CD30 was low [11]. Of note, CD30 expression was partial in our case. Weekly gemcitabine is an old drug regimen, very well tolerated in monotherapy, that has been used in a relapsed or refractory setting in other cutaneous T-cell lymphomas with notable efficacy. We thought to use the combination of these two drugs as it was successfully done in pediatric refractory Hodgkin lymphoma [12], since we needed a well-tolerated regimen at this point of the treatment.

The advantage of this treatment was its high tolerability and its efficacy allowing the patient to benefit from ASCT.

Further clinical studies are needed to evaluate better the efficiency of this treatment and its ability to bridge to an ASCT in this rare T-cell lymphoma entity.

CHOEP regimen: cyclophosphamide, 750 mg/m² i.v.; doxorubicin, 50 mg/m² i.v., vincristine, 2 mg i.v. on day 1; etoposide, 100 mg/m²/d i.v. on day 1 to 3 and prednisone, 100 mg/d p.o. on day 1 through 5 every 21 days.

Prophylactic intrathecal chemotherapy: methotrexate 15 mg, cytarabine 30 mg, methylprednisolone 30 mg.

B-CHP regimen: brentuximab-vedotin, 1.8 mg/kg i.v.; cyclophosphamide, 750 mg/m² i.v. and doxoru-

bicin, 50 mg/m² i.v. on day 1; prednisone 100 mg/d p.o. on day 1 to 5, every 21 days.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40164-021-00225-2>.

Additional file 1: Figure S1. PET-CT scan, ¹⁸F-FDG. **A** At diagnosis. **B** After 2 cycles of CHOEP. **C** After 2 cycles of B-CHP. **D** After 2 cycles of B-gemcitabine. **E** After 6 cycles of B-gemcitabine (pre-transplant). **F** Nine months after allotransplant.

Acknowledgements

Not applicable.

Authors' contributions

SV and AC were in charge of the patient, did the literature review and wrote the manuscript. LL performed the histological examination and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The patient gave his written consent to this publication.

Competing interests

The authors report no conflicts of interest in this work.

Author details

¹Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Rue du Bugnon 46, CH – 1011 Lausanne, Switzerland. ²Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.

Received: 8 March 2021 Accepted: 3 May 2021

Published online: 13 May 2021

References

1. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133(16):1703–14.
2. Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, et al. Primary cutaneous T-cell lymphomas showing gamma-delta ($\gamma\delta$) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous $\gamma\delta$ T-cell lymphomas. *Am J Surg Pathol*. 2017;41(2):204–15.
3. Toro JR, Liewehr DJ, Pabby N, Sorbara L, Raffeld M, Steinberg SM, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. *Blood*. 2003;101:3407–12.
4. Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. *Am J Surg Pathol*. 2012;36:1656–65.

5. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. EORTC Cutaneous Lymphoma Group. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood*. 2008;111(2):838.
6. Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. *Bone Marrow Transplant*. 2012;47(7):940–5.
7. Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, et al. Hematopoietic stem cell transplantation for primary cutaneous $\gamma\delta$ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. *J Am Acad Dermatol*. 2015;72(6):1010–5.
8. Terras S, Moritz RKC, Ditschkowski M, Beelen DW, Altmeyer P, Stücker M, et al. Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous γ/δ -T-cell lymphoma. *Acta Derm Venereol*. 2013;93:360–1.
9. Isulfi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M et al. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma delta T cell lymphomas. *Leuk Lymphoma* 2020;1–7
10. Kamijo H, Miyagaki T, Norimatsu Y, Awaji K, Oka T, Suga H, et al. Primary cutaneous $\gamma\delta$ T-cell lymphoma with unusual immunophenotype: A case report and review of published work. *J Dermatol*. 2020;47(3):300–5.
11. Talpur R, Chockalingam R, Wang C, Tetzlaff MT, Duvic M. A single-center experience with brentuximab vedotin in gamma delta T-Cell lymphoma. *Clin Lymphoma Myeloma Leuk*. 2016;16(2):e15–9.
12. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial. *Lancet Oncol*. 2018;19(9):1229–38.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

